Innovative Technologies for Stratified and Experimental Medicine
Lead Research Organisation:
University of Cambridge
Department Name: Clinical School
Abstract
We aim to build scientific and computing infrastructure in the School of Clinical Medicine at the University of Cambridge that will allow us i) to develop new technologies for measuring and imaging molecules in humans, and ii) to apply these technologies directly and immediately to major research programmes for understanding and treatment of cancer, metabolic disorders, and many other therapeutic areas.
Our strategic vision is that many diseases, that are traditionally diagnosed and treated as if all patients with the same diagnosis were largely the same, will become increasingly stratified. We expect that advances in biomedical science will demonstrate that there are in fact many different genetic and molecular pathways to the same clinical diagnosis. This has potentially important implications for more precise targeting of treatment: more refined diagnostic stratification of patients could identify more exactly which patients were most likely to respond to specific treatments. To realise this vision, we propose to create three new high-tech facilities for clinical research in Cambridge; a Stratified Medicine Core Laboratory (SMCL), a Molecular Imaging Centre (MIC), and a High Performance Hub for Informatics (HPHI).
The SMCL will allow us to measure a large number of peptides and other molecules in blood or other tissue samples with enhanced accuracy and sensitivity. The SMCL will also provide new facilities for next generation sequencing of DNA so that genetic variants driving disease can be identified in individual patients with sufficient precision and reliability to optimize diagnostic stratification and to inform clinical management immediately.
The MIC will allow us to measure molecules by imaging of patients, rather than by lab analysis of tissue samples. The MIC will comprise a new whole body scanner that can simultaneously collect MRI and PET data, as well as new facilities for manufacturing and administering labeled molecules as imaging probes to patients. The new radiochemistry facilities in the MIC will allow us to produce a much larger range and volume of radioactively labeled molecules that can be detected by PET imaging. The MIC will also support the technological development of dynamic nuclear polarization (DNP). This is a radically innovative method of molecular imaging which could potentially allow us to detect labeled molecules by MRI and without exposing patients to the risks of radioactivity. We will also upgrade one of our existing MRI scanners and locate it closer to the main focus of experimental medicine research in Cambridge.
The HPHI will provide the computational resources required to store and analyse the very large volumes of data produced by the SMCL and the MIC. It is also crucially important that the results of clinically actionable molecular analysis and imaging can be linked to individual patient records. This is key to "pulling through" the benefits of new technology to deliver stratified medicine in clinical practice. It is also important that the "big data" generated by the SMCL and MIC can be shared with the wider scientific community including our research partners elsewhere in the UK. We therefore propose to invest in new facilities for data storage, computational analysis, secure and ethically approved linkage of research data to clinical records, and data sharing. This computational hub will be managed as part of the University of Cambridge's new high performance computing facility.
These infrastructural investments have been planned to create an integrated platform for molecular and genetic stratification of human disease. They will enhance the impact of internationally leading research groups already established in Cambridge and they are coordinated with major infrastructural programmes already funded by the University or other agencies. They will underpin a step change in our capacity to harness the potential of new technologies to deliver our strategic vision.
Our strategic vision is that many diseases, that are traditionally diagnosed and treated as if all patients with the same diagnosis were largely the same, will become increasingly stratified. We expect that advances in biomedical science will demonstrate that there are in fact many different genetic and molecular pathways to the same clinical diagnosis. This has potentially important implications for more precise targeting of treatment: more refined diagnostic stratification of patients could identify more exactly which patients were most likely to respond to specific treatments. To realise this vision, we propose to create three new high-tech facilities for clinical research in Cambridge; a Stratified Medicine Core Laboratory (SMCL), a Molecular Imaging Centre (MIC), and a High Performance Hub for Informatics (HPHI).
The SMCL will allow us to measure a large number of peptides and other molecules in blood or other tissue samples with enhanced accuracy and sensitivity. The SMCL will also provide new facilities for next generation sequencing of DNA so that genetic variants driving disease can be identified in individual patients with sufficient precision and reliability to optimize diagnostic stratification and to inform clinical management immediately.
The MIC will allow us to measure molecules by imaging of patients, rather than by lab analysis of tissue samples. The MIC will comprise a new whole body scanner that can simultaneously collect MRI and PET data, as well as new facilities for manufacturing and administering labeled molecules as imaging probes to patients. The new radiochemistry facilities in the MIC will allow us to produce a much larger range and volume of radioactively labeled molecules that can be detected by PET imaging. The MIC will also support the technological development of dynamic nuclear polarization (DNP). This is a radically innovative method of molecular imaging which could potentially allow us to detect labeled molecules by MRI and without exposing patients to the risks of radioactivity. We will also upgrade one of our existing MRI scanners and locate it closer to the main focus of experimental medicine research in Cambridge.
The HPHI will provide the computational resources required to store and analyse the very large volumes of data produced by the SMCL and the MIC. It is also crucially important that the results of clinically actionable molecular analysis and imaging can be linked to individual patient records. This is key to "pulling through" the benefits of new technology to deliver stratified medicine in clinical practice. It is also important that the "big data" generated by the SMCL and MIC can be shared with the wider scientific community including our research partners elsewhere in the UK. We therefore propose to invest in new facilities for data storage, computational analysis, secure and ethically approved linkage of research data to clinical records, and data sharing. This computational hub will be managed as part of the University of Cambridge's new high performance computing facility.
These infrastructural investments have been planned to create an integrated platform for molecular and genetic stratification of human disease. They will enhance the impact of internationally leading research groups already established in Cambridge and they are coordinated with major infrastructural programmes already funded by the University or other agencies. They will underpin a step change in our capacity to harness the potential of new technologies to deliver our strategic vision.
Technical Summary
The vision is to use the explanatory and predictive power of genetics, biomolecular assays, and molecular imaging, to refine diagnostic and therapeutic stratification of patients with cancer, metabolic, neuroscience, cardiovascular and musculoskeletal disorders. To do this, we are seeking capital investment in 3 coordinated and strategically important areas for innovative technology and stratified medicine in Cambridge:
1) Stratified Medicine Core Laboratory: will deliver high-throughput, clinically actionable, sensitive and precise measures of multiple pathophysiologically important biomolecules. The SMCL will use new mass spectrometry immuno-assays for a wide range of peptides; extended capacity for existing multiplex assays; and next generation sequencing for deep genotyping.
2) Molecular Imaging Centre: will pioneer clinical translation of new technologies, such as dynamic nuclear polarization imaging and simultaneous PET/MRI imaging of radioligand binding (PET) combined with MRI markers of local tissue structure and function. The MIC will provide pharmacy support for quality controlled production and administration of PET radioligands and hyperpolarized molecules for DPN imaging. It will also include some enhanced capacity for 3T MRI in stratified and experimental medicine, optical imaging of epithelial dysplasia and neoplasia, and cell tracking in regenerative medicine.
3) High Performance Hub for Informatics: will deliver storage, analysis, sharing, and NHS clinical linkage, for the large volumes of complex data that will be generated by the SMCL and the MIC. This integrative computational hub will link together the two key biomedical platforms and provide the principal University portal for clinical "pull through" of stratified medicine to and from individual patient records in the NHS.
These investments will leverage international research strengths in Cambridge and are aligned with major investments by Cambridge University Health Partners.
1) Stratified Medicine Core Laboratory: will deliver high-throughput, clinically actionable, sensitive and precise measures of multiple pathophysiologically important biomolecules. The SMCL will use new mass spectrometry immuno-assays for a wide range of peptides; extended capacity for existing multiplex assays; and next generation sequencing for deep genotyping.
2) Molecular Imaging Centre: will pioneer clinical translation of new technologies, such as dynamic nuclear polarization imaging and simultaneous PET/MRI imaging of radioligand binding (PET) combined with MRI markers of local tissue structure and function. The MIC will provide pharmacy support for quality controlled production and administration of PET radioligands and hyperpolarized molecules for DPN imaging. It will also include some enhanced capacity for 3T MRI in stratified and experimental medicine, optical imaging of epithelial dysplasia and neoplasia, and cell tracking in regenerative medicine.
3) High Performance Hub for Informatics: will deliver storage, analysis, sharing, and NHS clinical linkage, for the large volumes of complex data that will be generated by the SMCL and the MIC. This integrative computational hub will link together the two key biomedical platforms and provide the principal University portal for clinical "pull through" of stratified medicine to and from individual patient records in the NHS.
These investments will leverage international research strengths in Cambridge and are aligned with major investments by Cambridge University Health Partners.
Planned Impact
No impact summary is required for applications to the Clinical Research Infrastructure call.
Organisations
- University of Cambridge (Lead Research Organisation)
- Siemens Healthcare (Collaboration)
- Siemens AG (Collaboration)
- GE Healthcare Limited (Collaboration)
- University of California, San Francisco (Collaboration)
- LGC Ltd (Collaboration)
- Mercodia AB (Collaboration)
- Ludwig Maximilian University of Munich (LMU Munich) (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
Publications
Adams NE
(2021)
GABAergic cortical network physiology in frontotemporal lobar degeneration.
in Brain : a journal of neurology
Althubaity N
(2022)
Choroid plexus enlargement is associated with neuroinflammation and reduction of blood brain barrier permeability in depression.
in NeuroImage. Clinical
Annus T
(2017)
The Down syndrome brain in the presence and absence of fibrillar ß-amyloidosis.
in Neurobiology of aging
Annus T
(2016)
The pattern of amyloid accumulation in the brains of adults with Down syndrome.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Azevedo T
(2022)
A deep graph neural network architecture for modelling spatio-temporal dynamics in resting-state functional MRI data.
in Medical image analysis
Belton M
(2016)
Hypoxia and tissue destruction in pulmonary TB.
in Thorax
Bethlehem R
(2020)
A normative modelling approach reveals age-atypical cortical thickness in a subgroup of males with autism spectrum disorder
in Communications Biology
Bethlehem R
(2021)
Brain charts for the human lifespan
Bethlehem RAI
(2022)
Brain charts for the human lifespan.
in Nature
Bethlehem RAI
(2020)
Dispersion of functional gradients across the adult lifespan.
in NeuroImage
Betts HM
(2016)
Synthesis, in Vitro Evaluation, and Radiolabeling of Fluorinated Puromycin Analogues: Potential Candidates for PET Imaging of Protein Synthesis.
in Journal of medicinal chemistry
Bevan Jones WR
(2016)
[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation.
in Annals of clinical and translational neurology
Bevan-Jones RW
(2018)
[18F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion.
in Annals of clinical and translational neurology
Bevan-Jones WR
(2020)
Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum.
in Brain : a journal of neurology
Bevan-Jones WR
(2019)
In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier.
in Annals of clinical and translational neurology
Bevan-Jones WR
(2018)
[18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia.
in Journal of neurology, neurosurgery, and psychiatry
Billing LJ
(2018)
Co-storage and release of insulin-like peptide-5, glucagon-like peptide-1 and peptideYY from murine and human colonic enteroendocrine cells.
in Molecular metabolism
Bocchetta M
(2021)
Looking beneath the surface: the importance of subcortical structures in frontotemporal dementia.
in Brain communications
Borchert RJ
(2016)
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.
in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Borchert RJ
(2016)
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.
in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Borroni B
(2022)
FRONTotemporal dementia Incidence European Research Study-FRONTIERS: Rationale and design.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Caldas C
(2022)
With one eye on the future.
in Cancer cell
Carmona-Bozo JC
(2021)
Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging.
in European radiology
Cash DM
(2018)
Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study.
in Neurobiology of aging
Cavaliere A
(2020)
Radiosynthesis of [18F]-Labelled Pro-Nucleotides (ProTides).
in Molecules (Basel, Switzerland)
Challis BG
(2015)
Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides.
in Endocrinology, diabetes & metabolism case reports
Chouliaras L
(2022)
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
in Journal of neurology, neurosurgery, and psychiatry
Church D
(2018)
Assessment and Management of Anti-Insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome.
in The Journal of clinical endocrinology and metabolism
Cole JH
(2017)
Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline.
in Neurobiology of aging
Cope TE
(2021)
Advances in neuroimaging to support translational medicine in dementia.
in Journal of neurology, neurosurgery, and psychiatry
Cope TE
(2018)
Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
in Brain : a journal of neurology
Coppola P
(2021)
Network dynamics scale with levels of awareness
Coppola P
(2022)
Network dynamics scale with levels of awareness.
in NeuroImage
Coppola P
(2022)
The complexity of the stream of consciousness
in Communications Biology
Cyranka M
(2019)
Abcc5 Knockout Mice Have Lower Fat Mass and Increased Levels of Circulating GLP-1.
in Obesity (Silver Spring, Md.)
Delso G
(2019)
Clinical Evaluation of 11 C-Met-Avid Pituitary Lesions Using a ZTE-Based AC Method
in IEEE Transactions on Radiation and Plasma Medical Sciences
Dolezalova N
(2021)
Accelerating cryoprotectant diffusion kinetics improves cryopreservation of pancreatic islets
in Scientific Reports
Dorfschmidt L
(2022)
Sexually divergent development of depression-related brain networks during healthy human adolescence.
in Science advances
Dye FS
(2019)
Characterisation of proguanylin expressing cells in the intestine - evidence for constitutive luminal secretion.
in Scientific reports
Ersche KD
(2021)
Reduced Glutamate Turnover in the Putamen Is Linked With Automatic Habits in Human Cocaine Addiction.
in Biological psychiatry
Fisher E
(2017)
Detection and Characterization of Small Molecule Interactions with Fibrillar Protein Aggregates Using Microscale Thermophoresis.
in ACS chemical neuroscience
Foreman RE
(2021)
Peptidomics: A Review of Clinical Applications and Methodologies.
in Journal of proteome research
Foreman RE
(2023)
Optimized LC-MS/MS Method for the Detection of ppCCK(21-44): A Surrogate to Monitor Human Cholecystokinin Secretion.
in Journal of proteome research
Foreman RE
(2022)
LC-MS/MS based detection of circulating proinsulin derived peptides in patients with altered pancreatic beta cell function.
in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
| Description | (Prof James Rowe, Cambridge PI) Dementias Platform UK (part 1) |
| Amount | £1,200,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 05/2021 |
| Description | (Prof James Rowe, Cambridge co-applicant) Dementias Platform UK (part 2) |
| Amount | £7,500,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 12/2025 |
| Description | BBSRC iCASE |
| Amount | £105,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | BBSRC iCASE studentship partnered with MedImmune (Sam Galvin) |
| Amount | £95,196 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2020 |
| Description | Bridging the gap: biophysical models of human frontotemporal lobar degeneration |
| Amount | £2,025,694 (GBP) |
| Funding ID | 220258/Z/20/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 03/2026 |
| Description | Cambridge Centre for Parkinsons Plus |
| Amount | $20,000,000 (USD) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 03/2022 |
| Description | Covid plasma LC-MS analysis |
| Amount | £4,875 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2020 |
| End | 07/2020 |
| Description | Dementia Platform UK |
| Amount | £2,677,560 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2014 |
| End | 03/2015 |
| Description | Liver disease peptidomics and proteomics |
| Amount | £24,350 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 12/2020 |
| Description | MRC Equip - World Class Labs award 2022/23 |
| Amount | £503,852 (GBP) |
| Funding ID | MC_PC_MR/X012417/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2023 |
| Description | MRC Equip - World Class Labs award 2022/23 - host contribution |
| Amount | £125,963 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2023 |
| Description | MRC MDU |
| Amount | £1,500,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2023 |
| Description | Medimmune grant |
| Amount | £272,857 (GBP) |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Sector | Private |
| Country | United Kingdom |
| Start | 06/2015 |
| End | 08/2017 |
| Description | NIHR Cambridge Biomedical Research Centre |
| Amount | £112,000,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | PET++: Improving Localisation, Diagnosis and Quantification in Clinical and Medical PET Imaging with Randomised Optimisation |
| Amount | £821,421 (GBP) |
| Funding ID | EP/S026045/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2022 |
| Description | Peptidomics of gestational diabetes |
| Amount | £3,400 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 03/2021 |
| Description | PhD in Clinical Biochemistry |
| Amount | £100,000 (GBP) |
| Funding ID | 2430172 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 03/2024 |
| Description | Restoring brain function: from cortical microcircuits to complex behaviours in neurodegenerative disease. |
| Amount | £1,908,236 (GBP) |
| Funding ID | 103838/Z/14/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2014 |
| End | 05/2021 |
| Description | Targeting the gut in metabolic disease |
| Amount | £2,381,203 (GBP) |
| Funding ID | 220271/Z/20/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 07/2025 |
| Title | Alteration of the plasma peptidome of gastrectomised patients during an OGTT |
| Description | Performing gastric bypass surgery on patients severely changes their gut hormone response to glucose. The plasma concentrations of Insulin and a number of associated incretin peptides are significantly raised shortly after ingestion of glucose. Typically the plasma concentrations of these peptides are monitored using immunoassays. A simple and high throughput plasma peptidomics approach was used to simulatneously monitor a large number of these peptides. Comparison of gastresctomised and control individuals showed significant increases of insulin, glucagon gene products, PYY and neurotensin. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | open dataset |
| URL | https://www.ebi.ac.uk/pride/archive/projects/PXD016690 |
| Title | Peptidomics of sorted enteroendocrine cells from human organoids |
| Description | A human organoid culture system was set up to grow enteroendocrine cells with a venus labeled on the glucagon gene promoter sequence. This enabled the sorting of glucagon gene positive cells from negative cells, thereby enabling the enrichment of glucagon producing cells for study. Both Venus positive and venus negative cell populations were collected and their peptidome was assessed using nano LC-MS/MS |
| Type Of Material | Database/Collection of data |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | open data |
| URL | https://www.ebi.ac.uk/pride/archive/projects/PXD017825 |
| Title | Peptidomics profiling of biopsies from the human jejunum before and after gastrectomy |
| Description | Profiling of the human jejunum peptidome before and after total gastrectomy. The study compares the peptidome of jejunum using intact mass spectrometry and database searching. These peptides included most gut hormones including proglucagon derived peptides, PYY, GIP, Motilin somatostatin and neurotensin amongst others. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | open dataset |
| URL | https://www.ebi.ac.uk/pride/archive/projects/PXD011498 |
| Title | Peptidomics profiling of human intestine |
| Description | The aim of the project is to generate a peptidomics map of gut hormone peptides along the gastrointestinal tract, starting with the stomach and including the duodenum, jejunum, ileum, ascending colon, sigmoid colon and rectum. The tissues would be collected after surgery and the peptide fraction extracted and anlysed by nano LC-MS to identify what peptide hormones are present. These data will then be used to compare against the human transcriptome, and also for comparison against equivent peptides from murine intestinal extracts. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | open dataset |
| URL | https://www.ebi.ac.uk/pride/archive/projects/PXD009788 |
| Title | Peptidomics profiling of murine intestine |
| Description | The aim of the project is to generate a peptidomics map of gut hormone peptides along the gastrointestinal tract, starting with the stomach and including the duodenum, jejunum, ileum, colon and rectum. The tissues would be collected after surgery and the peptide fraction extracted and anlysed by nano LC-MS to identify what peptide hormones are present. These data will then be used to compare against the murine transcriptome, and also for comparison against equivent peptides from human intestinal extracts. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | open dataset |
| URL | https://www.ebi.ac.uk/pride/archive/projects/PXD009796 |
| Title | Peptidomics profiling of the murine gut after vertical sleeve gastrectomy |
| Description | Profiling of the murine peptidome along the gastrointestinal tract and pancreas in vertical sleeve gastrectomy and sham operated mice. The study compares the peptidome of various portions of the GI tract using intact mass spectrometry and database searching. These peptides included most gut hormones including proglucagon derived peptides, PYY, GIP, somatostatin, neurotensin amongst others. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | open dataset |
| URL | https://www.ebi.ac.uk/pride/archive/projects/PXD011455 |
| Description | Collaboration with University of Edinburgh on Inflammation in dementia |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Intellectual expertise and collaborative links. A collaboration between University of Cambridge and University of Edinburgh linking Dementia Research Investigators with BRC and DPUK translational research programs. |
| Collaborator Contribution | Intellectual expertise and collaborative links. A collaboration between University of Cambridge and University of Edinburgh linking Dementia Research Investigators with BRC and DPUK translational research programs. |
| Impact | Providing direction and collaboration between dementia research investigators with BRC and DPUK translational research programs. |
| Start Year | 2021 |
| Description | GE MRC CRI PET/MRI |
| Organisation | GE Healthcare Limited |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The University, as part of the MRC Dementia Platform UK, will enable access to the new PET/MRI system and will share expertise and software for advanced image acquisition with the GE team. |
| Collaborator Contribution | GE have provided substantial cash contribution in the form of major discounts on list price of the PET/MRI system and related equipment, amounting to about 46% of list price. GE will additionally provide substantial in-kind support including: scientific and technical staff working on-site to help the University commissioning the new PET/MRI system and optimising its performance as part of the MRC Dementia Platform UK; PhD studentship; image analysis software; funds for start-up research projects on the new scanner. |
| Impact | No outputs yet |
| Start Year | 2015 |
| Description | LGC peptidomics |
| Organisation | LGC Ltd |
| Country | Global |
| Sector | Private |
| PI Contribution | Supporting a BBSRC iCASE studentship |
| Collaborator Contribution | Analysis and training |
| Impact | One publication to date |
| Start Year | 2017 |
| Description | Mercodia assay validation |
| Organisation | Mercodia AB |
| Country | Sweden |
| Sector | Private |
| PI Contribution | Mass spec analysis to validate Mercodia's glucagon assay. Measurement of patient samples using glucagon and glicentin assays to establish the cause of assay cross reactivity |
| Collaborator Contribution | Provision of assays and suggestions for protocol changes to remove cross-reactivity |
| Impact | Mercodia published a white paper outlining the collaboration and how it has impacted on the use of the glucagon assay |
| Start Year | 2018 |
| Description | ROWE GROUP: Dr M Malpetti Collaboration with Ludwig Maximilian University "TSPO PET in Tauopathies" |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Data analysis and expertise. |
| Collaborator Contribution | Data analysis and expertise. |
| Impact | Working on data collection and analysis with a view to future publication(s). |
| Start Year | 2021 |
| Description | ROWE Group: Dr M Malpetti "Tau-PET and domain-specific cognitive decline in Alzheimer's disease" |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Data generation and analysis |
| Collaborator Contribution | Data generation and analysis |
| Impact | Planned publications from collaboration. |
| Start Year | 2021 |
| Description | Siemens MRC CRI SKYRA |
| Organisation | Siemens AG |
| Department | Siemens Magnet Technology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The University will provide access to Siemens to the 3T SKYRA system and will release prototype pulse sequences for MRI data acquisition. |
| Collaborator Contribution | Siemens will commit technical and scientific staff to work alongside the University commissioning the new 3T SKYRA upgrade and optimising its performance. |
| Impact | TBC |
| Start Year | 2015 |
| Description | Siemens MRC CRI Skyra |
| Organisation | Siemens Healthcare |
| Country | Germany |
| Sector | Private |
| PI Contribution | The University of Cambridge in general and the Wolfson Brain Imaging Centre in particular have long-standing research collaboration agreements with Siemens. The University provides access to equipment, software and clinical data in support of the collaborative partnership with Siemens. |
| Collaborator Contribution | Siemens provided a substantial discount on the list price of SKYRA 3T upgrade. |
| Impact | No outputs yet from SKYRA upgrade. |
| Start Year | 2015 |
| Description | 13th annual Biomarkers Congress |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | An industrial congress bringing together a variety of industrial technologies for the measurement of biomarkers |
| Year(s) Of Engagement Activity | 2018 |
| Description | BBSRC symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | RF poster: Mass spectrometry vs immunoassay SG poster: Identification and in vivo characterisation of novel gut-derived peptides |
| Year(s) Of Engagement Activity | 2020 |
| Description | Cambridge City Council holiday club EM |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Science activities at Cambridge City Council drop-in holiday club for families |
| Year(s) Of Engagement Activity | 2021 |
| Description | Cambridgeshire Girlguiding Girls in STEM event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Cambridgeshire Girlguiding Girls in STEM event |
| Year(s) Of Engagement Activity | 2020 |
| Description | DG Poster at EASD study group 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "Developing 2D organoid cultures to study intracellular signalling in enteroendocrine cells" |
| Year(s) Of Engagement Activity | 2017 |
| Description | DG Poster at EASD study group 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | DG. Poster at Incretin Study Group: "Modelling human enteroendocrine cells using adult intestinal organoids" |
| Year(s) Of Engagement Activity | 2019 |
| Description | EM Talk at Society for Endocrinology conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk at Society for Endocrinology conference |
| Year(s) Of Engagement Activity | 2021 |
| Description | EM: Danish Diabetes Academy |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Poster presentation at Danish Diabetes academy - "Characterising stimulus-secretion coupling of the gut hormone motilin in human duodenal organoids" |
| Year(s) Of Engagement Activity | 2020 |
| Description | EM: Physiology of Obesity: From Mechanisms to Medicine |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Hormonal Regulation of Gut and Pancreas Physiology" - online webinar as part of Journal of Physiology 'Physiology of Obesity: From Mechanisms to Medicine' series |
| Year(s) Of Engagement Activity | 2020 |
| Description | FG Foster talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | FG gave invited lecture in the Department of Physiology, Development and Neuroscience at University of Cambridge. |
| Year(s) Of Engagement Activity | 2021 |
| Description | FG invited speaker at Keystone conference: Interconnection between the Gut, Brain and Microbiome for Metabolic Disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Triggered questions, collaborations and discussion with industry |
| Year(s) Of Engagement Activity | 2022 |
| Description | FG invited speaker at Metabolism in Action conference in Copenhagen |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Triggered questions and potential collaborations |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://cbmr.ku.dk/metabolism-in-action/ |
| Description | FG invited speaker at symposium on 100 years of Glucagon |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited talk at this symposium |
| Year(s) Of Engagement Activity | 2022 |
| URL | http://glucagonconference.com/ |
| Description | FG invited talk at 7th International Conference on Food Digestion, Cork |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker at this conference on food digestion. |
| Year(s) Of Engagement Activity | 2022 |
| URL | http://www.icfd2022.com |
| Description | FG invited talk at International scientific symposium - Gut / brain axis and regulation of food intake, organized by SFNCM/INRAE |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited talk at this symposium. Delivered virtually due to travel difficulties. Inspired questions from the audience |
| Year(s) Of Engagement Activity | 2022 |
| Description | FG talk at MRC-DTP symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | FG gave invited lecture at the annual symposium of the MRC-DTP students in Cambridge. |
| Year(s) Of Engagement Activity | 2021 |
| Description | FG talk at Milner Therapeutics Institute |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | FG gave invited lecture to the Milner Institute, which includes industrial audiences from around the world. The talk triggered many interesting questions. |
| Year(s) Of Engagement Activity | 2021 |
| Description | FR. presentation at Danish Diabetes Academy Winter School for postdoctoral researchers, at Higuerõn Hotel in Malaga/Spain 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "Incretins along the gut-pancreas-brain axis". |
| Year(s) Of Engagement Activity | 2019 |
| Description | FR: Mercodia Diagnostics, Uppsala. Invited speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Invited to talk to Mercodia about how our mass spec analysis methods complement their immunoassay development |
| Year(s) Of Engagement Activity | 2019 |
| Description | Interactive presentation of MRC CRI funded MRI technology for general public |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Cambridge Brainfest was a major public engagement event organised by Cambridge Neuroscience, which attracted 3000 visitors to the Corn Exchange in central Cambridge for two days of interactive exhibitions, short talks and other events. There were multiple exhibits and talks which featured the high performance MRI equipment funded by this award. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.neuroscience.cam.ac.uk/brainfest |
| Description | Movement Disorder Society International Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Gave a talk titled UHF 7T imaging to Progressive supranuclear palsy subgroup. |
| Year(s) Of Engagement Activity | 2021 |
| Description | PL. Poster at Incretin Study Group 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "SCFAs increase PYY but not GLP1 production in human L-cells " |
| Year(s) Of Engagement Activity | 2017 |
| Description | PL. Talk at Incretin Study Group 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | PL. Talk at Incretin Study Group. "Peptidomics to study enteroendocrine cells after bariatric surgery" |
| Year(s) Of Engagement Activity | 2019 |
| Description | Prof. James N Rowe: Brain Bus Initiative by MRC-CBU Researchers |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | The purpose of the BrainBus project is to provide a pivotal outreach experience to underprivileged children, exposing them to subjects, careers and role models which they would not otherwise access. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.mrc-cbu.cam.ac.uk/brain-bus/ |
| Description | REF Poster at SymBLS 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Size Exclusion Chromatography for Measuring Free and Antibody-bound Insulin in Hiratas Patients |
| Year(s) Of Engagement Activity | 2019 |
| Description | REF. Poster at DMDG open meeting 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | "Size Exclusion Chromatography for Measuring Free and Antibody-bound Insulin in Hiratas Patients" |
| Year(s) Of Engagement Activity | 2019 |
| Description | REF. Poster at EASD incretin study group 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | REF poster at EASD study group "A multiplex method for quantifying gut hormone peptides using Mass Spectrometry" |
| Year(s) Of Engagement Activity | 2019 |
| Description | REF. Poster at REID Bioanalytical Forum 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Immunoassay vs Mass Spectrometry -Measuring insulin and insulin analogues in human plasma |
| Year(s) Of Engagement Activity | 2019 |
| Description | RF: Murray Edwards Graduate Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | RF: Measuring insulin and insulin analogues in human plasma |
| Year(s) Of Engagement Activity | 2021 |
| Description | RGK Incretin 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | poster presentation at Incretin 2022. Lots of interest |
| Year(s) Of Engagement Activity | 2022 |
| Description | RGK Invited lecture on Mass Spectrometric analysis of Insulin at Anglian Ruskin University. Cambridge, UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | 1st March 2023. Invited lecture on Mass Spectrometric analysis of Insulin at Anglian Ruskin University. Cambridge, UK Audience: Staff and students Size: ~100 participants |
| Year(s) Of Engagement Activity | 2022 |
| Description | RGK Invited speaker at Reid Bioanalytical Forum. Cambourne, Cambridgeshire, UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | 5Th September 2022. Invited speaker at Reid Bioanalytical Forum. Cambourne, Cambridgeshire, UK Audience: Mainly bioanalytical scientists from industry Size: ~100 participants |
| Year(s) Of Engagement Activity | 2022 |
| Description | RGK Invited speaker at the Peptidomics Symposium. University of Copenhagen, Denmark |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 23rd August 2022. Invited speaker at the Peptidomics Symposium. University of Copenhagen, Denmark Audience: Academics and Clinicians Size: ~150 participants Outcome: Was invited to talk at the 2023 Danish Diabetes and Endocrine Academy conference |
| Year(s) Of Engagement Activity | 2022 |
| Description | RGK London Proteomics Discussion Group. London, UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Audience: Academic and industry researchers in the proteomics field Size: ~50 participants Outcome: Was invited to talk at the 2022 Reid Bioanalytical Forum |
| Year(s) Of Engagement Activity | 2022 |
| Description | RGK Proteomics Method Forum 2020 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Peptidomics: bridging the space between large and small molecule mass spectrometry |
| Year(s) Of Engagement Activity | 2020 |
| Description | RGK. American Society for Mass Spectrometry (ASMS) 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Waters user group meeting, presentation: "LC-MS analysis of plasma from patients with insulin autoimmune syndrome" Waters MS focused user meeting (Pharmaceutical track) Outcome: Video of talk available on Waters website, video interview on Select Science website, as well as an in-lab video interview. |
| Year(s) Of Engagement Activity | 2019 |
| Description | RGK. Poster at EASD incretin study group 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "Development of a rapid extraction method for the analysis of gut peptide hormones by LC-MS/MS" |
| Year(s) Of Engagement Activity | 2017 |
| Description | RGK. Poster at EASD incretin study group 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster at EASD incretin study group: "Proglucagon peptide analysis - will the real peptide please stand up!" |
| Year(s) Of Engagement Activity | 2019 |
| Description | RGK. Reid Bioanalytical Forum 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | "LC-MS analysis of plasma from patients with insulin autoimmune syndrome" Meeting focussing on broad bioanalytical approaches for wide range of analytes Outcome: Video interview by Bionalaysis zone, available on their website |
| Year(s) Of Engagement Activity | 2019 |
| Description | RGK. Waters UK and Ireland Clinical User Meeting 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Waters UK and Ireland Clinical User Meeting 2019 "LCMS Analysis of Proinsulin Derived Peptides" Waters meeting for users of MS systems in clinical environments |
| Year(s) Of Engagement Activity | 2019 |
| Description | RGK: Select Science Clinical Science Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plasma peptidomics - an untapped resource for biomarker analysis." |
| Year(s) Of Engagement Activity | 2020 |
| Description | SG. Poster at EASD incretin study group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | SG. Poster at EASD study group. "Characterisation of novel gut-derived peptides in vivo and in vitro" |
| Year(s) Of Engagement Activity | 2019 |
| Description | SG. Poster at EASD incretin study group 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | LC-MS based detection of insulin-like peptide 5 in primary colonic cultures |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk by Dr N Holland - ROWE Group at Cambrige Imaging Festival |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk title "Synaptic imaging in dementia and neurodegenerative disease" |
| Year(s) Of Engagement Activity | 2021 |
| Description | Talk by Prof Rowe at Cambridge Imaging Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk given at Cambridge Imaging Festival titled "New directions in dementia imaging" |
| Year(s) Of Engagement Activity | 2021 |
| Description | Tutor on the Drug Metabolism and Discussion Group (DMDG) large molecule bioanalysis course |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Richard Kay was Tutor on the Drug Metabolism and Discussion Group (DMDG) large molecule bioanalysis course. A three day course held at Loughborough University, focussed on the dissemination of knowledge for developing bioanalytical methodologies for large molecule analytes. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Tutor on the Drug Metabolism and Discussion Group (DMDG) large molecule bioanalysis course |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Richard Kay was Tutor on the Drug Metabolism and Discussion Group (DMDG) large molecule bioanalysis course. A three day course held at Loughborough University, focussed on the dissemination of knowledge for developing bioanalytical methodologies for large molecule analytes. |
| Year(s) Of Engagement Activity | 2017 |
| Description | University of Cambridge & AZ science symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | SG Presentation: Utilising LC/MS to identify novel bioactive gut-derived peptides and peptidomic differences in type 2 diabetic human islets FG Panel discussion |
| Year(s) Of Engagement Activity | 2020 |
| Description | Workshop Chair Dr M Malpetti (Rowe Group): Combining imaging modalities with machine learning |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Workshop chair of "Combining imaging modalities with machine learning" session at ERC DEMON workshop 2021 |
| Year(s) Of Engagement Activity | 2021 |